SEC Form 4 · accession 0001553878-17-000069

ALNYLAM PHARMACEUTICALS, INC. · ALNY

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Executive Officer · Director

Period of report

Nov 22, 2017

Accepted (ET)

Nov 24, 2017 · 6:55 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001178670

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Nov 22, 2017	M	73,415	$31.39	A	223,125	D
Common Stock^F2	Nov 22, 2017	S	25,263	$129.97	D	197,862	D
Common Stock^F3	Nov 22, 2017	S	25,036	$130.88	D	172,826	D
Common Stock^F4	Nov 22, 2017	S	20,433	$131.82	D	152,393	D
Common Stock^F5	Nov 22, 2017	S	2,683	$132.73	D	149,710	D
Common Stock^F6	holding	—	—		—	2,960	I	By Managed Account

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7,F1	$31.39	Nov 22, 2017	M	73,415	D	—	Dec 12, 2017	Common Stock	73,415	0	D

F1All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 13, 2017. The 73,415 options exercised and sold by the reporting person were due to expire on December 12, 2017.
F2Sale prices ranged from $129.39 to $130.35.
F3Sale prices ranged from $130.38 to $131.37.
F4Sale prices ranged from $131.38 to $132.36.
F5Sale prices ranged from $132.38 to $133.34.
F6The reporting person owns 2,960 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
F7The stock option vested as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.